Abstract
To the Editor—Kumar et al [1] reported on the role of single bamlanivimab in preventing hospitalization associated with coronavirus disease 2019 (COVID-19). There is scarce evidence of prevalence of emergent variants in patients treated with bamlanivimab [2]. But very little is known about treatment-emergent variants in the B.1.1.7 lineage, which is by now the dominant strain throughout Europe and North America. We hereby report the selection of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) immune escape mutations in a B.1.1.7 variant 7 days after administration of single bamlanivimab in a patient with deeply impaired cellular immunity (Figure 1). The patient newly diagnosed with acute myeloid leukemia first tested positive for SARS-CoV-2 at day 11 after the start of chemotherapy. Initially, the cycle threshold (Ct) was above 30 and melting point analysis at day 15 suggested B.1.1.7 as the causative agent of this...
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.